Merck Sharpe and Dohme report allergy drug trial results

Merck Sharpe and Dohme has published positive results from a clinical trial of a new treatment for grass pollen allergy among child patients.

The phase III trial showed that the company’s investigational sublingual grass (phleum pratense) allergy immunotherapy tablet had a positive effect in protecting against the ailment and its symptoms, such as runny nose and itchy eyes.

This means that the drug, which is indicated for patients aged between five and 17 years old, was able to achieve its primary target endpoint in the trial.

Dr James Fish, executive director of global scientific affairs at Merck Research Laboratories, stated that the company is encouraged by the results and will be looking to develop the treatment further.

He added: “Merck is committed to developing respiratory products that provide physicians with a wide range of treatment options to help their patients suffering from allergies.”

Last month, the company reported encouraging results from a phase III clinical trial of Isentress, a treatment for HIV.